Skip to content
    Clinical Trials

    Response-Adapted Organ Preservation in Early and Intermediate Rectal Cancer

    Bach et alThe Lancet Oncology

    Response-Adapted Organ Preservation in Early and Intermediate Rectal Cancer
    The international, multicenter, open-label, randomized phase 2/3 STAR-TREC trial evaluated response-adapted organ preservation strategies comparing long-course chemoradiotherapy (LCCRT) against short-course radiotherapy (SCRT) in patients with early-stage and intermediate-stage rectal cancer. Early 12-month findings support the response-adapted organ-preservation approach, with LCCRT demonstrating greater effectiveness than SCRT at achieving organ preservation. Furthermore, organ-preservation strategies may lessen treatment-related toxicity compared with standard primary total mesorectal excision (TME). Extended follow-up is required to assess the prespecified 30-month endpoint and establish definitive oncological and functional outcomes.

    Key Takeaways

    • In patients with early-stage and intermediate-stage rectal cancer, long-course chemoradiotherapy appears more effective than short-course radiotherapy at 12 months for response-adapted organ preservation.
    • A response-adapted organ-preservation strategy may reduce treatment-related toxicity compared with primary total mesorectal excision.
    Read the original sourceThe Lancet Oncology